Life Sciences & Biotechnology

Life Sciences & Biotechnology Research and Advisory

Home

/

Our Expertise

/

Life Sciences & Biotechnology Research and Advisory

Financial modeling, market intelligence, investment research, and regulatory analysis for biotech companies, biopharma innovators, MedTech firms, and the healthcare-focused investors and PE/VC funds active across the life sciences value chain.

The Sector Today

The life sciences sector is moving at a pace that makes most conventional investment and business intelligence frameworks insufficient. Breakthrough therapies in oncology, rare diseases, and metabolic disorders are compressing development timelines. The shift toward value-based care is changing the commercial model for drugs that reach market. Platform technologies such as gene therapy, RNA therapeutics, and antibody-drug conjugates are creating new valuation methodologies that traditional comparable company analysis struggles to address accurately.

For PE and VC investors, the challenge is compound. Clinical-stage assets require an assessment of mechanism of action, regulatory pathway, and competitive landscape that goes beyond financial modeling. Health technology assessment and payer dynamics increasingly determine whether a drug that reaches approval actually generates the revenue the pre-launch model projected. Real-world evidence requirements are shaping market access strategy from early in the development cycle, not retrospectively. The information arbitrage in biotech investing lies in understanding these dynamics before they become consensus.

For biotech companies and biopharma innovators, the commercial challenge is in translating scientific credibility into investor confidence. Clinical data that is understood by KOLs and scientific advisors needs to be presented in a format that investment committees and payer negotiators can evaluate. That translation work, from the laboratory to the boardroom, requires domain expertise that sits across both. In GCC markets specifically, this challenge has a distinct dimension: Saudi Arabia's genomics investment programme and the UAE's local pharmaceutical manufacturing mandates under Vision 2030 and UAE Industrial Strategy 2030 are creating significant biotech capital flows that require analytical teams who understand both the Western clinical development pathway and the SFDA and MoHAP regulatory frameworks that govern approval and market access in those markets.

The assets that attract capital in biotech are the ones where the clinical thesis is credible, the regulatory pathway is clear, and the commercial model reflects what the payer environment will actually support rather than what the base case assumed.

Who We Serve

Biotech and Biopharma Companies

Biotech startups and scale-ups, biopharma companies preparing for IPO or a licensing transaction, and MedTech firms preparing for commercial scale who need financial modeling, market opportunity assessment, investor communication materials, and commercial strategy grounded in scientific and regulatory reality.

Healthcare-Focused PE and VC Investors

PE firms and VC funds with healthcare and life sciences mandates that need independent investment research, target screening, clinical asset evaluation, and portfolio monitoring across development-stage and commercial-stage biotech investments.

Scientific Advisors, KOLs, and RWE Analysts

Scientific advisors, key opinion leaders, and real-world evidence analysts working alongside investment teams or company management on therapeutic area intelligence, regulatory strategy, and commercial validation.

What We Deliver

Business Valuation & Capital Advisory · Market Opportunity Assessment · Regulatory Intelligence & RWE · Biotech Investment Research · Competitive Intelligence · Commercialisation Strategy · Investor Communication

Business Valuation and Capital Advisory

Financial modeling, valuation, and deal support for biotech and biopharma companies and the investors evaluating them across licensing, M&A, and capital-raising transactions. The analytical work covers platform technology valuation, pipeline asset assessment, and the investor materials required to move a transaction forward.

Pre-IPO support

financial models, investor-ready pitch decks, and research reports built from regulatory filings, management commentary, and clinical data to support biotech fundraising mandates.

M&A intelligence

tracking of private biotech activity, extraction of deal rationale and comparable transaction data, and strategic fit analysis for licensing and M&A processes.

Platform technology valuation

DCF and probability-weighted NPV models for development-stage assets, incorporating clinical success probability, regulatory pathway risk, and market access assumptions.

Partnership and collaboration intelligence

identification of partnership synergies across development, manufacturing, and commercial operations to support business development decisions.

Deal structuring support

analytical inputs for milestone structuring, royalty rate benchmarking, and licensing term assessment.

Analytical Outputs We Produce

Probability-weighted NPV models for clinical-stage biotech assets incorporating regulatory pathway risk and market access assumptions.

Epidemiology-driven TAM/SAM/SOM analysis across eleven therapeutic areas with disease burden and treatment rate inputs.

Clinical pipeline benchmarking reports covering mechanism of action, trial design, IP landscape, and competitive positioning.

Pre-IPO financial models and investor-ready pitch decks for biotech fundraising mandates.

RWE monitoring dashboards tracking safety signals, regulatory updates, and therapeutic effectiveness across portfolio assets.

KOL engagement maps and stakeholder ecosystem analyses for commercial launch preparation.

HTA submission support materials and payer engagement strategy frameworks.

M&A comparable transaction analysis and licensing deal structure benchmarking.

Life Sciences in Practice

Case Study

Obesity Drug Market Entry: Strategic Intelligence for a GLP-1 Asset

A healthcare-focused PE fund evaluating an investment in a GLP-1 obesity drug platform engaged Perusal Global for market sizing, competitive landscape analysis, regulatory pathway mapping, and commercial model development. The work covered epidemiology-driven TAM analysis across five geographies, assessment of approved and development-stage GLP-1 and competing mechanisms, FDA and EMA regulatory pathway review, payer dynamics and HTA precedent analysis, and a probability-weighted NPV model for the asset. The output informed the fund's investment committee submission and shaped the commercial assumptions in the deal model.

Frequently Asked Questions

Clinical-stage biotech assets are valued using a probability-weighted net present value model, not a conventional DCF. The model applies a risk-adjusted discount rate to peak sales projections for each pipeline asset, weighted by the clinical success probability at each development stage. Clinical success rates vary significantly by therapeutic area and mechanism of action: a Phase 2 oncology asset carries a materially different success probability than a Phase 2 rare disease asset with Breakthrough Therapy Designation. The NPV is then adjusted for patent life, time to market, and regulatory pathway assumptions. Getting the market access and pricing assumptions right is as important as the clinical probability because peak sales projections that do not reflect current payer dynamics will overstate the asset value regardless of how precisely the clinical probability is modeled.

Commercial due diligence for a specialty biopharma investment covers five analytical areas. First, independent validation of the market opportunity: epidemiology-grounded TAM analysis and treatment rate assumptions that go beyond the company's own projections. Second, competitive landscape assessment: approved and development-stage products in the same therapeutic area, mechanism of action differentiation, and the realistic probability that the target's positioning holds as the competitive set evolves. Third, payer and HTA dynamics: whether the drug's clinical profile supports the pricing assumption and what the reimbursement pathway looks like in each key market. Fourth, earnings quality: whether reported revenue and margin figures reflect sustainable commercial performance or are inflated by accounting treatment, one-time payments, or milestone recognition. Fifth, management assessment: track record on prior pipeline execution and regulatory submission history.

Health Technology Assessment determines whether a drug receives reimbursement in a given market and at what price, which means the HTA outcome determines the revenue assumption in the commercial model rather than being an afterthought to it. In markets with formal HTA processes, including the UK, Germany, France, and increasingly in GCC markets, a drug with strong clinical trial data can still face restricted or conditional reimbursement if the incremental benefit over existing standard of care is not considered sufficient at the proposed price. The commercial model for a new drug entering any of these markets needs to be built around realistic HTA scenarios, not the company's preferred pricing assumption. This is particularly relevant for GLP-1 and cardiometabolic assets where multiple approved products are competing for the same payer budget.

Biotech licensing and M&A transactions require a layered analytical framework. The first layer is asset-level: mechanism of action assessment, clinical data quality, IP landscape, regulatory pathway, and competitive positioning. The second layer is transaction structure: for licensing deals, milestone structure, royalty rate benchmarking against comparable transactions, and the risk allocation between licensor and licensee. For M&A, the analysis extends to the acquirer's pipeline fit, commercial synergies, and the probability that the acquired asset continues to progress post-acquisition. The third layer is the financial model: probability-weighted NPV for the asset, accretion and dilution analysis for the acquirer, and scenario analysis across the key value drivers. Comparable transaction analysis provides the market evidence but biotech comparables require careful selection because asset-level differences are more significant than in most other sectors.

Post-approval real-world evidence monitoring tracks four categories of data continuously. Safety signals: adverse event reports, pharmacovigilance submissions, and any signals that might trigger regulatory action or label restrictions. Effectiveness data: real-world treatment outcomes compared to the clinical trial population, which often differ because the approved indication in practice covers a broader and less selected patient group. Market access: payer formulary decisions, step therapy requirements, and any restrictions that are affecting prescription rates relative to the launch model assumptions. Competitive dynamics: new competitor approvals, label expansions for existing products, and prescriber switching data. The monitoring output feeds directly into the portfolio valuation update and the fund's assessment of whether the commercial thesis is tracking to plan.

A biotech market entry or commercial launch assessment typically covers epidemiology-driven TAM and SAM sizing, treatment rate and patient funnel modeling, payer landscape and HTA pathway analysis, competitive positioning assessment, KOL mapping and stakeholder ecosystem analysis, and a financial model for the launch scenario under evaluation. For a single geography, the assessment is typically completed within six to eight weeks. For a multi-geography launch covering the US, major European markets, and GCC, twelve to sixteen weeks is a realistic timeline depending on data availability and the number of payer systems being modeled independently.

Ready to Work?

The first conversation is about the specific decision your team is facing: a clinical asset that needs a commercial model, a therapeutic area that needs sizing before a capital commitment, a fund portfolio that needs monitoring across R&D milestones, or a biotech company approaching investors for the first time. We will tell you precisely how we approach it.